Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

Nikolai Zhelev, Elena Kuzmanova, Marilena Spanou

    Research output: Contribution to journalMeeting Abstract

    Abstract

    Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.
    Original languageEnglish
    Pages (from-to)S81
    Number of pages1
    JournalJournal of Biotechnology
    Volume256
    Issue numbersuppl
    Early online date16 Aug 2017
    DOIs
    Publication statusPublished - 30 Aug 2017
    EventEuropean biotechnology Congress 2017 - Rixos Libertas, Dubrovnik, Croatia
    Duration: 25 May 201727 May 2017
    http://eurobiotech2017.eu/?p=Home

    Fingerprint

    Thymidine Kinase
    Tumor Biomarkers
    High Pressure Liquid Chromatography
    Serum
    Isotopes
    Biomarkers
    Breast Neoplasms
    Antibodies
    Neoplasms
    Therapeutics

    Cite this

    Zhelev, Nikolai ; Kuzmanova, Elena ; Spanou, Marilena. / Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker. In: Journal of Biotechnology. 2017 ; Vol. 256, No. suppl. pp. S81.
    @article{54ed2fb3a00f49a3894425bd193548ef,
    title = "Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker",
    abstract = "Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.",
    author = "Nikolai Zhelev and Elena Kuzmanova and Marilena Spanou",
    year = "2017",
    month = "8",
    day = "30",
    doi = "10.1016/j.jbiotec.2017.06.1079",
    language = "English",
    volume = "256",
    pages = "S81",
    journal = "Journal of Biotechnology",
    issn = "0168-1656",
    publisher = "Elsevier Science B.V.",
    number = "suppl",

    }

    Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker. / Zhelev, Nikolai; Kuzmanova, Elena; Spanou, Marilena.

    In: Journal of Biotechnology, Vol. 256, No. suppl, 30.08.2017, p. S81.

    Research output: Contribution to journalMeeting Abstract

    TY - JOUR

    T1 - Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

    AU - Zhelev, Nikolai

    AU - Kuzmanova, Elena

    AU - Spanou, Marilena

    PY - 2017/8/30

    Y1 - 2017/8/30

    N2 - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.

    AB - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.

    U2 - 10.1016/j.jbiotec.2017.06.1079

    DO - 10.1016/j.jbiotec.2017.06.1079

    M3 - Meeting Abstract

    VL - 256

    SP - S81

    JO - Journal of Biotechnology

    JF - Journal of Biotechnology

    SN - 0168-1656

    IS - suppl

    ER -